Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4
Document Type and Number:
WIPO Patent Application WO/2023/042996
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for preventing or treating focal segmental glomerulosclerosis acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a pharmaceutical composition including, as an active ingredient, a sphingolipid compound which does not cause cardiovascular side effects by acting as a functional antagonist for S1PR1 and S1PR4 and has an effect of preventing or treating focal segmental glomerulosclerosis.
Inventors:
LEE BONG YONG (KR)
PARK YANG HAE (KR)
KIM EUN JEONG (KR)
PARK YANG HAE (KR)
KIM EUN JEONG (KR)
Application Number:
PCT/KR2022/007784
Publication Date:
March 23, 2023
Filing Date:
May 31, 2022
Export Citation:
Assignee:
NEXTGEN BIOSCIENCE (KR)
International Classes:
A61P13/12; A61K31/4192; A61P37/06
Foreign References:
| AU2021202271A1 | 2021-05-06 | |||
| KR20170087813A | 2017-07-31 | |||
| AU2019264073A1 | 2020-11-26 |
Attorney, Agent or Firm:
ERUUM & LEEON INTELLECLTUAL PROPERTY LAW FIRM et al. (KR)
Download PDF:
Previous Patent: WEARABLE DEVICE COMPRISING SPEAKER
Next Patent: CERAMIC PAPER AND METHOD FOR PREPARING SAME
Next Patent: CERAMIC PAPER AND METHOD FOR PREPARING SAME